Sartorius AG · XETR:SRT
Sartorius — Sartorius Stedim Biotech — Investor Presentation (February 2026)
36 slides from Sartorius's investor presentation, February 2026
Slide 1: Simplifying Progress – Sartorius Stedim Biotech Investor Presentation
Simplifying Progress Sartorius Stedim Biotech Investor Presentation February 2026
Slide 2: Agenda
Sartorius Stedim Biotech Group Agenda Overview | Strategy FY 2025 results | FY 2026 outlook Appendix 2
Slide 3: Sartorius Stedim Biotech at a glance
Sartorius Stedim Biotech Group Sartorius Stedim Biotech at a glance ~€3.0bn Sales revenue ~13% Our mission Sales CAGR 2015-2025 ~30.8% EBITDA margin1 We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling ~85% the development of new and be
Slide 4: Track record of profitable sales growth above market
Sartorius Stedim Biotech Group Track record of profitable sales growth above market Sales revenue; EBITDA margin1 CAGR ~13% ▪ Increase Increase share ofshare of wallet wallet by by ~€3.0bn addressing addressing criticalcritical stepssteps at customers at customers ▪ Strong focus on recurring revenue
Slide 5: Covering most steps of the biopharmaceutical manufacturing process
Sartorius Stedim Biotech Group Covering most steps of the biopharmaceutical manufacturing process ▪ Differentiated by the range and completeness of the Culture media Seed Scale-up Production portfolio preparation cultivation ▪ Excellent positioning in key single-use technologies UPSTREAM ▪ Internati
Slide 6: Pioneer and leader in the growing single-use technology market
Sartorius Stedim Biotech Group Pioneer and leader in the growing single-use technology market Single-use market penetration expected to increase from ~35% to ~75% ▪ Single-use products offer advantages over conventional stainless-steel devices ▪ Capex|Opex reduction over entire lifecycle ▪ Reduced r
Slide 7: Competitive product offering
Sartorius Stedim Biotech Group Competitive product offering Sartorius Peer 1 Peer 2 Peer 3 Filtration Fluid Management Fermentation Purification Cell Culture Media Pie charts indicate completeness of product offering 7
Slide 8: Generating revenue throughout the lifecycle of a biopharma drug
Sartorius Stedim Biotech Group Generating revenue throughout the lifecycle of a biopharma drug Products specified into customers’ validated processes; recurring revenues with Attractive business consumables after approval of the drug by health authorities (e.g. FDA, EMA) model Stage Pre-clinical Cli
Slide 9: Limited dependence on individual accounts
Sartorius Stedim Biotech Group Limited dependence on individual accounts Long-term business relationships with leading global Limited dependence on individual accounts (bio-) pharma companies Sales to Top 50 customers in 2025, € in millions 1000 ~58% ~61% 800 ~53% ~45% 600 ~30% 400 200 0 Top 10 11 t
Slide 10: Resilient global setup, well prepared for further growth
Sartorius Stedim Biotech Group Resilient global setup, well prepared for further growth Global Capex 393 Capex Major projects ~X% in millions of €; 340 resilience composition Regular expansion ratio in % 12.2 13.3 ~3% Capitalized R&D ~2% Redundant Maintenance ~3% capacities 2024 2025 Freiburg, Germa
Slide 11: Attractive market environment offers strong growth opportunities
Sartorius Stedim Biotech Group Attractive market environment offers strong growth opportunities Growing and aging population Biologics are gaining importance2 >9.5 billion people by 20501 World population over age 65 in 2050 Sales share of biologics in 2030 ~1.6bn ~57% ~10% CAGR³ biopharma market 20
Slide 12: Addressing customer needs across all types of biopharma drugs
Sartorius Stedim Biotech Group Addressing customer needs across all types of biopharma drugs 1796 1818 1982 1986 2012 / 2017 2020 2023 Blood Recombinant Monoclonal Cell & gene mRNA CRISPR Vaccines products proteins antibodies therapies vaccines gene therapy Established Biopharmaceuticals Next Genera
Slide 13: Fundamental biopharma growth drivers intact, additional dynamics from new modalities
Sartorius Stedim Biotech Group Fundamental biopharma growth drivers intact, additional dynamics from the new modalities segment ~30% of biopharma pipeline is focusing on CGT1 Number of commercial processes is expanding rapidly 79 approved CGT globally1 ~70% ~30% Other CGT biologics 33 CGT approvals
Slide 14: Extensive technology platform for cell and gene therapy applications
Sartorius Stedim Biotech Group Extensive technology platform for cell and gene therapy applications Biological Albumedix Polyplus CellGenix Xell Up & downstream solutions Industries Cell culture Growth factors Media and Recombinant Transfection Cell line development, media and cytokines supplements
Slide 15: Biosimilars: Strong growth, big opportunities
Sartorius Stedim Biotech Group Biosimilars: Strong growth, big opportunities Major blockbuster biologics are going off-patent Time-to-market is key as only the first providers are most likely profitable Several approvals in Asia and Europe; U.S. at the beginning For now, relatively small market but
Slide 16: High innovation dynamics in Biopharma
Sartorius Stedim Biotech Group High innovation dynamics in Biopharma Development of new Increased efficiency New tools and Future drug drugs and vaccines possible in the methods required manufacturing is must be accelerated, production of 'classic' e.g. for novel cell and more automated, e.g. throug
Slide 17: Integration of innovative technologies is a Sartorius core competency
Sartorius Stedim Biotech Group Integration of innovative technologies is a Sartorius core competency Acquisitions Cooperations Own Product Development of complementary technologies with partners leading in their fields in areas of core competencies Cell cultivation Process Separation Artificial tech
Slide 18: Consistent M&A strategy focusing on two defined areas
Sartorius Stedim Biotech Group Consistent M&A strategy focusing on two defined areas Unique portfolio for Intensified technologies Advanced Therapies for downstream processing Biological WaterSep Danaher chromatography BIA Separations CellGenix (2020) (2020) Industries (2020) (2021) (2019) Albumedix
Slide 19: Leveraging digital tools for faster process development and cost-efficient bioprocessing
Sartorius Stedim Biotech Group Leveraging digital tools for faster process development and cost- efficient bioprocessing Combination of bioprocess sensors, analyzers and software to… Expected high …collect, monitor and control quality- Faster results New insights impact of AI, in- critical parameter
Slide 20: Agenda
Sartorius Stedim Biotech Group Agenda Overview | Strategy FY 2025 results | FY 2026 outlook Appendix 20
Slide 21: Delivered on 2025 guidance
Sartorius Stedim Biotech Group Delivered on 2025 guidance 2025 Guidance Initial (quant.) guidance Updated guidance FY 2025 (prelim.) Sales revenue growth + ~7 (+/- approx. 2 pp) +~9 +9.6 (in %, cc)1 Ul EBITDA margin (in %) ~30 to ~31 ~31 30.8 Capex (in %) ~13.0 ~13.0 13.3 Net debt | ul EBITDA(x) app
Slide 22: Strong profitable growth driven by consumables demand
Sartorius Stedim Biotech Group Strong profitable growth driven by consumables demand Sales revenue | € in millions Ul. EBITDA & margin | € in millions +9.6% cc | +6.7% +17.3% 2,967 2,780 30.8% 28.0% 914 779 FY 2024 FY 2025 FY 2024 FY 2025 ▪ LTM BtB ratio consistently >1 ▪ Double-digit sales growth i
Slide 23: All regions contributed to positive business development
Sartorius Stedim Biotech Group All regions contributed to positive business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.3% cc +11.8% cc +10.7% cc 1,241 1,159 982 1,053 639 673 FY 2024 FY 2025 FY 2024 FY 2025 FY
Slide 24: Strong profit performance; good cash generation; capex in line with plan
Sartorius Stedim Biotech Group Strong profit performance; good cash generation; capex in line with plan Sartorius Stedim Biotech FY 2024 FY 2025 in % in millions of € Underlying net profit1,2 338 428 +26.7 ▪ Overproportionate increase in net result and underlying EPS Underlying EPS3 3.49 4.40 +26.0
Slide 25: Strong balance sheet; deleveraging well on track
Sartorius Stedim Biotech Group Strong balance sheet; deleveraging well on track Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Dec. 31, 5.0 in millions of € unless otherwise specified 2024 2025 3,000 4.0 Equity ratio in % 48.7 51.7 2,0
Slide 26: Confident outlook 2026
Sartorius Stedim Biotech Group Confident outlook 2026 Guidance 2026 Sales revenue growth1 Underlying EBITDA margin Sartorius Stedim Biotech Group ~6% to ~10% Slightly above 31% ▪ Sales growth includes ~1pp contribution from US tariff-related surcharges For financial modelling on SSB level ▪ Capex ra
Slide 27: Appendix
27 Appendix SARTORI
Slide 28: Reasons to invest
Sartorius Stedim Biotech Group Reasons to invest Clear strategy, Strong fundamental Competitive, consistent growth drivers differentiated implementation product portfolio High-performance, High share of Ambitious team, resilient production recurring revenues strong customer focus and R&D infrastruct
Slide 29: Board of Sartorius Stedim Biotech S.A. group
Sartorius Stedim Biotech Group Board of Sartorius Stedim Biotech S.A. group Dr. Dr. René Romaine Pascale Susan Cecile Anne-Marie Lothar Christopher Share of Michael Fáber Fernandes Boissel Dexter Dussart Graffin Kappich Nowers independent Grosse CEO Employee members Chairman Representative Audit & S
Slide 30: A sampling of the product portfolio
Sartorius Stedim Biotech Group A sampling of the product portfolio Filtration Purification Fermentation Fluid management 30
Slide 31: Single-use allows manufacturers to mitigate investment risks
Sartorius Stedim Biotech Group Single-use allows manufacturers to mitigate investment risks ▪ Construction of stainless-steel based facilities takes longer and is more complex compared to single-use ▪ Therefore, investment in stainless-steel facilities has to start in early clinical phase II ▪ The c
Slide 32: Share price performance
Sartorius Stedim Biotech Group Share price performance 250% 200% 150% 100% 50% 0% Sartorius (pref.) Sartorius (ord.) Sartorius Stedim Biotech DAX SBF 120 ISIN FR0013154002 Indices SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC Ticker DIM All Shares |CAC Healthcare | MSCI Europe | STOX
Slide 33: Corporate responsibility & further financial information
Sartorius Stedim Biotech Group Corporate responsibility & further financial information To Sartorius, sustainability means operating Please click below for further information: responsibly over the long term – with respect to business partners, employees and society as well as to natural resources.
Slide 34: Contacts and Financial calendar
Sartorius Stedim Biotech Group Contacts and Financial calendar Petra Müller ▪ March 17, 2026 Head of Investor Relations Capital Markets Day, Goettingen +49.551.308.6035 ▪ March 24, 2026 petra.mueller2@sartorius.com Annual Shareholders’ Meeting Mirko Koch ▪ April 23, 2026 Publication Q1 Results 2026
Slide 35: Disclaimer
Sartorius Stedim Biotech Group Disclaimer This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward- looking statements are realistic, we cannot
Slide 36: Simplifying Progress
Simplifying Progress Scan or click here to visit our IR website.
Sartorius Stedim Biotech — Investor Presentation (February 2026) on 6ix